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Mutagenicity Testing of 9-NSubstituted
Adenines and Their NOxidation Products
by J. W. Gorrod,' C. Ioannides,2 S. R Lam,' and
S. Neville2
Adenine together with certain 9-N-substituted derivatives such as 9-methyl, 9-benzyl, 9-benzhydryl, and
9-trityl were tested against Salmonella typhimurium strains TA97, TA98, and TA100 in the absence and
presence of rat hepatic S9 prepared from Aroclor 1254 pretreated rats. All compounds were positive toward
TA98 in the presence of the metabolic activating system, whereas they all lacked mutagenic activity in the
absence ofS9,andtowardTA97andTA100withorwithoutS9whentestedat100ng/plate.Asimilarpattern was
observed forthecorresponding1-N-oxides.6-Hydroxylaminopurine was notmutagenictowardTA100at100ng/
plate,whereasitwastoxictowardTA97andTA98atthis level.Whentestedat 1 ng/plate, hydroxylaminopurine
wasstill toxictoTA98butproducedtwicethespontaneousreversion ratetoTA97withoutmetabolicactivation.
Surprisingly, 9-methyl-6-hydroxylaminopurine was only active toward TA98 in the presence of S9, whereas
9-benzyl-6-hydroxylaminopurine was highlyactive toward TA97 andTA100 in the absence ofS9and even more
active in the presence of S9. This compound was inactive toward TA98 in the absence of S9. The results
generally support the concept that nuclear N-oxidation of aminoazaheterocycles is a detoxication process,
whereas N-hydroxylation ofthe exo amino group is a toxication reaction.
Introduction
Aminoazaheterocylcles are a class of compounds char-
acterized by an aromatic nuclear nitrogen atom(s)
together with an ortho exo-amino group. These com-
pounds have diverse pharmacological properties, are
widely used in clinical medicine, and occur as natural
products [(1-3) Fig. 1] or are formed as metabolites of
drugs (Fig. 2). They may also be produced during the
cooking of foods or pyrolysis ofproteins and amino acids
[(4,5) Fig. 3].
The metabolism of many ofthese compounds has been
studied (1-3), and generally it has been observed that
compounds used in clinical medicine are not genotoxic and
are metabolized by oxidation at one or more nuclear nitro-
gens (6-12), whereas those produced by pyrolysis are
potent mutagens (13) and are metabolized by N-hydrox-
ylation ofthe exo amino group (14-16). This has led to the
concept (1-3) thatnuclearN-oxidation ofaminoazahetero-
cycles is a detoxication process, whereas N-hydroxylation
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ofthe exo amino group is a toxication reaction (Fig. 4).
Ortho aminoazaheterocycles are usually oxidized at
eitherone orotheroftheconstituentnitrogens.Onlyinthe
case ofthe nonmutagenic 2-aminopyridine has both path-
ways of N-oxidation been observed (17,18); di-N-
oxygenation has never been found with these compounds.
Directproofofthetoxication/detoxication conceptofartho
aminoazaheterocycle metabolism and toxicity has there-
fore not been possible.
Adenine (Fig. 5) is a naturally occurringartho aminoaza-
heterocycle that is capable ofbeing chemically converted
toboththe1-N-oxide (19)and6-hydroxylaminopurine (20).
Similar pairs of N-oxidation products may be prepared
from 9-substituted adenines which themselves differ in
their physicochemical properties (12). Certain 1-N-oxides
and 6-hydroxylamine derivatives of 9-substituted purine
have been compared with their parent compounds and
used to probe the toxication/detoxication concept using
various Salmonella typhimurium strains with and with-
out a hepatic activation system.
Materials and Methods
Chemicals
Adenine, 9-methyladenine (MA), 9-benzyladenine (BA),
and their corresponding 1-N-oxides (ANO, MANO, and
BANO) and 6-hydroxylamines, i.e., 6-hydroxylamino-GORROD ETAL.
purine (HP) and 6-hydroxylamino-9-methylpurine (HMP)
were obtained as described previously (11). 9-Benz-
hydryladenine (BHA), 9-benzhydryladenine-1-N-oxide
(BHANO), 9-trityladenine (TA), and 9-trityladenine-1-N-
oxide (TANO) were prepared according to previously
reported methods (12).
6-Hydroxylamino-9-benzylpurine (HBP) was synthe-
sized by the reaction of 9-benzyl-6-chloropurine with an
ethanolic solution of hydroxylamine. Hydroxylamine
hydrochloride (7.8 g) dissolved inboiling, absolute ethanol
(130mL)wasmixedwithasolutionofpotassiumhydroxide
(6.8 g) in hotethanol (25mL). Thepotassiumchloride that
formed was filtered off and washed three times with hot
ethanol (15 mL). The ethanolic hydroxylamine solution
obtained was added to a boiling solution of 9-benzyl-6-
chloropurine (1.87g),prepared according tothemethod of
Montgomery and Temple (21), in absolute ethanol (78mL).
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FIGURE 1. Examples of some medicinal and nat
cycles.
Themixturewasrefluxedfor6hr, afterwhichthe solution
was left to cool overnight. HBP precipitated; was col-
lected, and recrystallized from absolute ethanol (yield
78%, melting point 226-228°C with decomposition).
(Found: C,59.71: H,4.47; N,28.95%; C12H11N50 requires
C, 59.74; H, 4.60; N, 29.03%.)
Determination ofMutagenic Potential
The compounds were tested against Salmonella
typhimurium strains TA97, TA98, and TA100 exactly as
described by Maron and Ames (22) at a concentration of
100 ng/plate or less dissolved in dimethylsulfoxide (1 ,ug/
mL).Theviabilityofthesystemswerecheckedbyincorpo-
ratingeither9-aminoacridine (20jig/plate; TA97),2-nitro-
fluorene (2 ,ug/plate; TA98), or methyl-N-nitro-N-
nitrosoguanidine (2 ,ug/plate; TA100). 2-Aminoanthracene
(5 ,ug/plate)wasusedwithall strainsinthepresenceofan
S9 metabolic activating system. The S9 metabolic activat-
ing system was prepared frormL rats that had been pre-
treated with Aroclor 1254 (a single IP dose of500 mg/kg,
the animalswerekilled on day5 afteradministration) and
contained S9 at a 10% v/v suspension.
GuaRsulian
Nucleic acid base Results and Discussion
Adenine, together with its 1-N-oxide and 6-N-hydroxy
Nx >> derivative (Fig. 5) were tested for mutagenicity using /
-S Ns~ SalmonellatyphimuriumTA97,TA98,andTA100strains.
Amiphenazole Also tested were the 9-methyl and 9-benzyl derivatives
Respiratory Stimulant and the 9-benzhydryl and 9-trityl derivatives of adenine
andadenine-1-N-oxide. 9-Benzhydryl-6-hydroxylamino-
N NH purine and 9-trityl-6-hydroxylaminopurine were not
N-<\ N§CI tested due to the difficulty in obtaining the pure com-
NCH. pounds (23).Theresultsofthemutagenicitystudycarried
Cycloguanil out in the absence or presence of a metabolic activating
Antimalarial system are presented in Table 1.
The results in the absence of a metabolic activating
system may be summarized as follows: a) the parent
purines did notdemonstrate enhancedmutagenicitywhen
jX NH. compared with the spontaneous reversion rate; b) the
purine-1-N-oxides hadvirtuallyidentical mutagenic prop-
Zoxazolamine erties as the parent bases; c) the 6-N-hydroxylamines,
Muscle Relaxant whereavailable,weregenerallymoretoxicandmoremuta-
genicthanthebaseortheN-oxidetowardTA97andTA100
but not toward TA98. This suggests that they may be
NHJ,<J1°NH. actingby either anintercalating orbase-pairmechanism. o) 0 N However, this was not true for the 9-methyl compound,
which. showed only a slight increase in mutagenic activity
Thiazolesulphone coinpxv-d to either base or 1-N-oxide toward TA97 and
Antileprotic lacked mutagenicity, at the level tested, toward TA100. A
clear mutagenic response, over the base and 1-N-oxide, o NH due to exo-aminoN-hydroxylation was observedusingthe CXNJIC,NH, 9-benzyl series even though the latter compound was
NH, N NH, tested at only 50 ng/plate compared with 100 ng/plate for
Amiloride the parent purine and 1-N-oxide.
In the presence of a metabolic activating system, the
results observed were a) the parent compounds were
ural aminoazahetero- inactivetowardTA97andTA100,whereastheywereactive
towardTA98; b) the1-N-oxideswere alsoinactivetowards
22MUTAGENICITY OF 9-N-ALKYLADENINES AND N-OXIDATION PRODUCTS
CH,-O N
NH,
Doxazosin
<N orN NH
S-N
VKN7
VK 774
0
COOH
N >N N
CH,ri-CH3
CH,-o 0 N7 yNH,
CH,-O N
NH,
/NyNH,
N
0
N, COOH
NH, 'N N
IHCH
Piromidic Acid
FIGURE 2. Examples ofaminoazaheterocycles produced during metabolism of drugs.
NH,
N
CH,
N N
NH,
N=
H,C N cM.
H,C N
7,8-DiMelQlx
CH,
-N
N "H,
N
H
Trp-P-2
NH,
N
CH,
eQ H,
MeIQ
N NH,
N
cM,
Glu-P-1
NH,
H
AaC
NH,
N
M,C N N' C ,
N
MelQx
N NH,
N
N
Glu-P-2
CH,
H
MeAcaC
NH,
N H,C N C H,
N CH.
4,8-DiMelQx
CM,
N
H\ tNH,
N
H CH,
Trp-P-1
Ch,
P N
N N
PhIP
FIGUIRE 3. Examples ofmutagenic aminoazaheterocycles formed during cooking offood or pyrolysis ofproteins and certain amino acids.
TA97 and TA100 but again were active towards TA98; c)
the hydroxylamines were active toward both TA97 and
TA100 as well as TA98. Additionally, in all cases where
mutagenic activity was demonstrated in the absence of a
metabolic system, an enhanced mutagenic effect was
observed after incorporation of the metabolic activating
system. In the case of compounds that failed to demon-
stratemutagenicactivity(e.g.,bases and1-N-oxidesinthe
absence of an activating system) addition of the system
allowed mutagenic activity to be expressed.
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FIGURE 5. Structures of (a) 9-substituted adenine, (b) adenine-1-N-
oxide, and (c) 6-hydroxylaminopurine. (I) R=H; (II) R=CH3; (III)
R=CH2C6H5; (IV) R=CH(C6H5)2; (V) R = C(C6H5)3.
Previous studies on the metabolism -of 9-substituted-
adenines showed that they were only coverted to 1-N-
oxides byaphenobarbital-inducible cytochrome P450 spe-
cies, presumably CYP2B. This enzyme failed to oxidize
adenine to adenine-1-N-oxide (11,12,24). Using rats pre-
treated with either 3-methylcholanthrene or isosafrole
(inducersofCYP1), ClementandKunze (25)demonstrated
that adenine, at high substrate concentrations, was con-
verted to 6-hydroxylaminopurine. It is likely that the
activating system prepared from rats pretreated with
Aroclor 1254 (an inducer ofboth CYP1 and CYP2B), used
in the present study is also capable ofmetabolizing ade-
ninestothecorresponding6-hydroxylaminopurines. How-
ever, as the 6-hydroxylaminopurines tested generally
showedanenhancedactivityinthepresenceoftheactivat-
ing system, it may be that further oxidation of the 6-hy-
droxylamino function is occurring, producing a nitroso or
nitro compound or an intermediate nitrenium ion or ni-
troxide radical (26,27). Such intermediates are known to
react with cellular macromolecules and may initiate their
mutagenic effect via this mechanism (28,29).
The results obtained in the present work are generally
consistent with previous observations on the genotoxicity
of N-oxidized derivatives of aminopurines. Thus, 6-hy-
droxylaminopurine induced mitotic inhibition and nuclear
degeneration in mouse sarcoma 180 cells in vitro and
prolonged the survival time ofmice bearing sarcoma 180
ascites cells (30,31). This substance is genotoxic to both
eukaryotes and prokaryotes (32-36).
Our results agree with McCartney et al. (35), who also
found that adenine was inactive toward TA100, whereas
6-hydroxylaminopurine was mutagenic. This latter com-
pound was found by these authors to be inactive toward
TA98, whereas in our experiments we found that HP was
extremely toxic toward this strain.
Ithasbeenproposedthat HP actsbyforming adesoxy-
nucleoside triphosphate, which is incorporated into DNA
(36), although other evidence (35) indicates thatthe muta-
genic activity of 6-hydroxylaminopurine is caused by
directadductformationratherthanbybaseincorporation.
This is supported by results obtained using a series ofE.
lable 1. Mutagenicity ofadenine derivatives toward S. typhimurium strains with (+) and without (-) a metabolic activating system.a
TA97 TA98 TA100
Compound
Spontaneous reversion rate
I
a. Adenine
b. Adenine-1-N-oxide
c. 6-Hydroxylaminopurine (1 ng/plate)
II
a. 9-Methyladenine
b. 9-Methyladenine-1-N-oxide
c. 9-Methyl-6-hydroxylaminopurine
III
a. 9-Benzyladenine
b. 9-Benzyladenine-1-N-oxide
c. 9-Benzyl-6-hydroxylaminopurine (50 ng/plate)
IV
a. 9-Benzhydryladenine
b. 9-Benzhydryladenine-1-N-oxide
c. 9-Benzhydryl-6-hydroxylaminopurine
V
65 + 1
63 ± 5
71 ± 11
132 ± 55
73 ± 5
61 ± 1
88 ± 4
71 ± 11
76 ± 4
799 ± 18
69 ± 16
66 ± 7
89 ± 1
104 + 12
95 ± 11
113 + 4
88 + 4
99 ± 10
103 ± 10
92 ± 16
100 ± 14
1330 ± 216
88 ± 4
91 ± 7
16 + 5 21 + 4
21 ± 5
19 + 6
toxic
21 + 6
24 ± 2
21 ± 1
17 ± 1
20 + 2
17 ± 3
76 + 11
124 ± 15
toxic
88 ± 20
118 + 9
96 ± 11
131 + 18
92 + 11
69 ± 8
99 ± 7
108 + 15
105 ± 10
121 ± 13
111 + 5
105 ± 3
93 ± 15
105 ± 9
102 ± 23
944 ± 105
18 +3 113 ± 13 89 ±4
19 +4 107 ± 11 96 + 12
+
108 ± 13
103 ± 26
117 + 20
170 + 22
113 ± 7
109 ± 3
123 + 14
123 ± 16
109 ± 3
1664 ± 98
129 ± 13
131 ± 13
a.9-Trityladenine 73 ± 5 101 ± 14 18 ± 9 102 ± 7 86 ± 1 83 ± 18
b. 9-Trityladenine-1-N-oxide 61 ± 7 98 ± 9 23 ± 6 102 ± 41 81 ± 41 106 ± 13
c. 9-Trityl-6-hydroxylaminopurine - - - - - -
Positive control 1456 600 302 865 3464 3240
aResults arepresented ashistidinerevertants/plate (mean ± SD oftriplicates). Eachstudywasrepeated atleastonce. Unlessotherwisestated,each
compound was tested at a concentration of100 ng/plate. Compounds were dissolved in dimethylsulfoxide (1 ,ug/mL). The activation system contained
hepatic S9 fraction (10% v/v) from Aroclor 1254 pretreated rats.
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coli mutants, which led Murray (37) to propose that "the
major mechanism for hydroxylaminopurine is due to the
reaction of these compounds with the 06 position of
guanine and the 04 position ofthymine."
Administration of 6-hydroxylaminopurine to 10 female
Wistarratsproduced onlyonetumorat15monthsandwas
completely inactive in Sprague-Dawley rats; the authors
(38) concluded that "its oncogenicity is marginal at best."
Barrett (33), citing the same publication (38), interprets
thedataasmeaningthatHPisweaklycarcinogenic; thisis
supportedbythepresentstudieswhere HPonlydisplayed
a weak mutagenic response. 6-Hydroxylaminopurine is
also teratogenic (30).
Studies on the toxicity of adenine-1-N-oxide are more
controversial. In an early publication (39), it was stated
that "Administration of adenine-1-N-oxide for 6 months
failed to produce tumors in any tissues of 13 rats during
the experimental period of 15 months." In a later paper
(38), it was reported that "Subsequent assays have led to
tumours in both Sprague-Dawley and Wistar rats; at a
dose level of10 mg/week for 26weeks, tumours have been
induced at the site of injection of 33 of 41 rats."
Adenine-1-N-oxide was inactive as a sulfate acceptor (40),
aprocess that hasbeen proposed as the second activating
step for hydroxylamines and hydroxamic acids (26,27),
although invivo acetylation to1-acetoxyadenine produced
a reactive species toward Bacillus subtilis-transforming
DNA and can be considered as a weak mutagen (41). The
role ofpurine N-oxides in cancer has been reviewed (43).
The limited results we have obtained intheAmes muta-
genicity test are not inconsistent with the metabolic-N-
oxygenation hypothesis of toxication/detoxication of ami-
noazaheterocycles, which is a good guide to genotoxicity.
Clearly, morebases andtheircorrespondingN-oxides and
hydroxylamines need tobeprepared andtested atvarious
concentrations using additional sophisticated bacterial
test strains lacking specific xenobiotic-metabolizing
enzyme systems before the concept canbefullysubstanti-
ated.
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